A Phase 1, Open Label, Randomized, Parallel Group Study to Assess the Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2017
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 05 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 10 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 17 Jun 2014 New trial record